Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

416 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Targeted radioactive therapy for prostate cancer.
De Giorgi U, Conteduca V, Gurioli G, Matteucci F, Paganelli G. De Giorgi U, et al. Among authors: paganelli g. Lancet. 2021 Aug 7;398(10299):487-488. doi: 10.1016/S0140-6736(21)01336-2. Lancet. 2021. PMID: 34364517 No abstract available.
Plasma tumour DNA as an early indicator of treatment response in metastatic castration-resistant prostate cancer.
Conteduca V, Wetterskog D, Scarpi E, Romanel A, Gurioli G, Jayaram A, Lolli C, Tandefelt DG, Schepisi G, Casadei C, Wingate A, Matteucci F, Paganelli G, Gonzalez-Billalabeitia E, Demichelis F, De Giorgi U, Attard G. Conteduca V, et al. Among authors: paganelli g. Br J Cancer. 2020 Sep;123(6):982-987. doi: 10.1038/s41416-020-0969-5. Epub 2020 Jul 16. Br J Cancer. 2020. PMID: 32669676 Free PMC article.
Circulating androgen receptor gene amplification and resistance to 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer: results of a Phase 2 trial.
De Giorgi U, Sansovini M, Severi S, Nicolini S, Monti M, Gurioli G, Foca F, Casadei C, Conteduca V, Celli M, Di Iorio V, Calistri D, Matteucci F, von Eyben FE, Attard G, Paganelli G. De Giorgi U, et al. Among authors: paganelli g. Br J Cancer. 2021 Oct;125(9):1226-1232. doi: 10.1038/s41416-021-01508-5. Epub 2021 Jul 31. Br J Cancer. 2021. PMID: 34333554 Free PMC article. Clinical Trial.
Combining liquid biopsy and functional imaging analysis in metastatic castration-resistant prostate cancer helps predict treatment outcome.
Conteduca V, Scarpi E, Caroli P, Lolli C, Gurioli G, Brighi N, Poti G, Farolfi A, Altavilla A, Schepisi G, Matteucci F, Paganelli G, De Giorgi U. Conteduca V, et al. Among authors: paganelli g. Mol Oncol. 2022 Jan;16(2):538-548. doi: 10.1002/1878-0261.13120. Epub 2021 Nov 9. Mol Oncol. 2022. PMID: 34657387 Free PMC article.
(18)F-Fluorocholine PET/CT for early response assessment in patients with metastatic castration-resistant prostate cancer treated with enzalutamide.
De Giorgi U, Caroli P, Scarpi E, Conteduca V, Burgio SL, Menna C, Moretti A, Galassi R, Rossi L, Amadori D, Paganelli G, Matteucci F. De Giorgi U, et al. Among authors: paganelli g. Eur J Nucl Med Mol Imaging. 2015 Jul;42(8):1276-83. doi: 10.1007/s00259-015-3042-5. Epub 2015 Mar 26. Eur J Nucl Med Mol Imaging. 2015. PMID: 25808631
Erratum to: (18)F-Fluorocholine PET/CT for early response assessment in patients with metastatic castration-resistant prostate cancer treated with enzalutamide.
De Giorgi U, Caroli P, Scarpi E, Conteduca V, Burgio SL, Menna C, Moretti A, Galassi R, Rossi L, Amadori D, Paganelli G, Matteucci F. De Giorgi U, et al. Among authors: paganelli g. Eur J Nucl Med Mol Imaging. 2015 Jul;42(8):1337-8. doi: 10.1007/s00259-015-3069-7. Eur J Nucl Med Mol Imaging. 2015. PMID: 25900277 No abstract available.
Prognostic value of 18F-choline PET/CT metabolic parameters in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide.
Caroli P, De Giorgi U, Scarpi E, Fantini L, Moretti A, Galassi R, Celli M, Conteduca V, Rossi L, Bianchi E, Paganelli G, Matteucci F. Caroli P, et al. Among authors: paganelli g. Eur J Nucl Med Mol Imaging. 2018 Mar;45(3):348-354. doi: 10.1007/s00259-017-3866-2. Epub 2017 Nov 6. Eur J Nucl Med Mol Imaging. 2018. PMID: 29110067 Clinical Trial.
416 results